Abstract
Objectives: To review the evidence of the involvement of the Wnt signalling pathway in mood disorders and in the action of drugs used to treat these disorders.
Methods: We performed a careful PubMed search using as keywords all possible terms relevant to the Wnt pathway and crossing them with each of four areas, i.e., developmental effects, behavioural effects, mood disorders, and drugs used in their treatment. Papers were selected on the basis of their content and their data used for discussion. Results: Neurodevelopmental and behavioural data point to the possibility of involvement of the Wnt pathway in the pathophysiology of mood disorders. Clinical and post-mortem data are not sufficient to corroborate a definite role for Wnt alterations in any mood disorder. Combining genetic and pharmacological data, we may state that glycogen synthase kinase is the key molecule in bipolar disorder, as it is connected with many other signalling pathways that were shown to be involved in mood disorders, while Wnt molecules in the hippocampus appear to be mainly involved in depressive disorders. Conclusions: Altered Wnt signalling may play a role in the pathophysiology of mood disorders, although not a central one. It is premature to draw conclusions regarding the possible usefulness of Wnt manipulations in the treatment of mood disorders.Keywords: Wingless (Wnt) signalling, Mood Disorders, Bipolar Disorder, Major Depression, Antidepressant Drugs, Mood Stabilising Agents, Antipsychotic Drugs
Current Neuropharmacology
Title:The Wnt Pathway in Mood Disorders
Volume: 10 Issue: 3
Author(s): Giulia Serra, Paolo Girardi, Ferdinando Nicoletti, Antonio Del Casale, Chiara Rapinesi, Daniele Serata, Alexia E. Koukopoulos, Stefano Maria Tamorri, Valeria Savoja, Giovanni Manfredi, Silvia Romano, Gabriele Sani, Carla Ludovica Telesforo, Nicoletta Girardi, Matteo Caloro, Alessio Simonetti, Giulio Maria Porfiri, Isabella Panaccione, Giorgio D. Kotzalidis, Alberto Maria Forte and Flavia Napoletano
Affiliation:
Keywords: Wingless (Wnt) signalling, Mood Disorders, Bipolar Disorder, Major Depression, Antidepressant Drugs, Mood Stabilising Agents, Antipsychotic Drugs
Abstract: Objectives: To review the evidence of the involvement of the Wnt signalling pathway in mood disorders and in the action of drugs used to treat these disorders.
Methods: We performed a careful PubMed search using as keywords all possible terms relevant to the Wnt pathway and crossing them with each of four areas, i.e., developmental effects, behavioural effects, mood disorders, and drugs used in their treatment. Papers were selected on the basis of their content and their data used for discussion. Results: Neurodevelopmental and behavioural data point to the possibility of involvement of the Wnt pathway in the pathophysiology of mood disorders. Clinical and post-mortem data are not sufficient to corroborate a definite role for Wnt alterations in any mood disorder. Combining genetic and pharmacological data, we may state that glycogen synthase kinase is the key molecule in bipolar disorder, as it is connected with many other signalling pathways that were shown to be involved in mood disorders, while Wnt molecules in the hippocampus appear to be mainly involved in depressive disorders. Conclusions: Altered Wnt signalling may play a role in the pathophysiology of mood disorders, although not a central one. It is premature to draw conclusions regarding the possible usefulness of Wnt manipulations in the treatment of mood disorders.Export Options
About this article
Cite this article as:
Serra Giulia, Girardi Paolo, Nicoletti Ferdinando, Del Casale Antonio, Rapinesi Chiara, Serata Daniele, E. Koukopoulos Alexia, Maria Tamorri Stefano, Savoja Valeria, Manfredi Giovanni, Romano Silvia, Sani Gabriele, Ludovica Telesforo Carla, Girardi Nicoletta, Caloro Matteo, Simonetti Alessio, Maria Porfiri Giulio, Panaccione Isabella, D. Kotzalidis Giorgio, Maria Forte Alberto and Napoletano Flavia, The Wnt Pathway in Mood Disorders, Current Neuropharmacology 2012; 10 (3) . https://dx.doi.org/10.2174/157015912803217279
DOI https://dx.doi.org/10.2174/157015912803217279 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Potential Role of (-)-Epigallocatechin-3-Gallate (EGCG) in the Secondary Prevention of Alzheimer Disease
Current Drug Targets Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors
Current Medicinal Chemistry A New Investigational Perspective for Purines Against Glioblastoma Invasiveness
Current Drug Targets Circumventing Immune Tolerance Through Epigenetic Modification
Current Pharmaceutical Design Modulation of Mitochondrial and Epigenetic Targets by Polyphenols-rich Extract from Araucaria angustifolia in Larynx Carcinoma
Anti-Cancer Agents in Medicinal Chemistry SANTAVAC ™: A Novel Universal Antigen Composition for Developing Cancer Vaccines
Recent Patents on Biotechnology Neuroprotective Role of Agmatine in Neurological Diseases
Current Neuropharmacology Sphingolipid Metabolism and Drug Resistance in Hematological Malignancies
Anti-Cancer Agents in Medicinal Chemistry Bitropic D3 Dopamine Receptor Selective Compounds s Potential Antipsychotics
Current Pharmaceutical Design To Die or Not to Die: That is the Autophagic Question
Current Molecular Medicine Discovering New Treatments for Alzheimer's Disease by Repurposing Approved Medications
Current Topics in Medicinal Chemistry Plant Coumestans: Recent Advances and Future Perspectives in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry From Rapid to Delayed and Remote Postconditioning: The Evolving Concept of Ischemic Postconditioning in Brain Ischemia
Current Drug Targets Targeting Telomerase by Antisense-Based Approaches: Perspectives for New Anti-Cancer Therapies
Current Pharmaceutical Design MicroRNA in Cervical Carcinogenesis: Window of Therapeutic Potential
Current Women`s Health Reviews Overview of microRNA Target Analysis Tools
Current Bioinformatics Computational Medicinal Chemistry for Rational Drug Design: Identification of Novel Chemical Structures with Potential Anti-Tuberculosis Activity
Current Topics in Medicinal Chemistry Role of GSK-3 in Cardiac Health: Focusing on Cardiac Remodeling and Heart Failure
Current Drug Targets Levels of Estrogen Receptors α and β in Frontal Cortex of Patients with Alzheimers Disease: Relationship to Mini-Mental State Examination Scores
Current Alzheimer Research Assessing Activation States in Microglia
CNS & Neurological Disorders - Drug Targets